Northwestern Medicine researchers reported a safety signal tying GLP-1 receptor agonists to increased incidence of fainting and dizziness, consistent with more hypotensive events. The finding adds to the drug-class discussion as GLP-1s expand beyond diabetes into broader obesity and cardiometabolic indications. The report focuses on clinically relevant adverse episodes associated with blood pressure decreases, underscoring the importance of monitoring for vulnerable patients and refining prescribing guidance. The results are expected to be folded into ongoing safety surveillance and real-world risk management.